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Nicotinamide in Friedreich’s ataxia: useful or not?
Friedreich’s ataxia is an autosomal recessive 
neurodegenerative disorder caused by mutations in 
the frataxin gene (FXN), leading to progressive ataxia, 
cardiomyopathy, scoliosis, and various other clinical 
features.1 Most patients have GAA repeat expansions 
in intron 1 of FXN, leading to decreased concentrations 
of frataxin protein and downstream mitochondrial 
dysfunction. The GAA repeats lead to gene silencing 
through heterochromatin formation, and decreased 
transcription of FXN mRNA. The coding region of the 
mRNA and the aminoacid sequence of the protein 
are normal, but the amount of protein produced is 
reduced; as a result, reversal of the epigenetic changes 
(such as histone deacetylation) represents a potential 
therapeutic strategy in Friedreich’s ataxia. Inhibitors 
of histone deacetylase (HDAC) have been reported to 
increase frataxin concentrations in cell culture and in 
animal models of Friedreich’s ataxia.2,3
In an open-label, dose-escalation study reported 
in The Lancet, Vincenzo Libri and colleagues4 note an 
increase in FXN mRNA expression and frataxin protein 
concentration in peripheral blood mononuclear cells 
in patients given nicotinamide, a drug that has HDAC 
inhibitor activity when given at high concentrations. 
Ten adult patients with Friedreich’s ataxia from the 
UK were given single doses (phase 1) and repeated 
daily doses of 2–8 g oral nicotinamide for 5 days 
(phase 2) and 8 weeks (phase 3). In phase 1, a single 
dose of up to 8 g (about 200 times higher than the 
typical recommended daily allowance for nicotinamide 
as a vitamin [B3]5) led to an increase in frataxin 
concentration in peripheral blood mononuclear 
cells, and this eﬀ ect increased with increasing dose 
(p=0·0004). In phases 2 and 3, repeated daily dosing 
at 3·5–6 g resulted in a sustained and signiﬁ cant 
(p<0·0001) upregulation of frataxin expression, 
which was associated with changes in chromatin 
structure (a signiﬁ cant reduction methylation at 
aminoacid position 9 of the histone H3 tail and a 
non-signiﬁ cant increase in H3 acetylation at the FXN 
locus). The investigators did not report any signiﬁ cant 
improvements in neurological measures, as assessed 
by the scale for the assessment and rating of ataxia 
and the spinocerebellar ataxia functional index.
These results are of interest for several reasons. 
First, although nicotinamide has several potential 
Emmanuel Futier
Département Anesthésie et Réanimation, Hôpital Estaing, 
CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France
efutier@chu-clermontferrand.fr
I have received consulting fees from General Electric Medical Systems and 
Baxter, lecture fees from Fresenius Kabi, and accommodation and travel 
reimbursement for meetings from Fisher & Paykel Healthcare.
1 Pearse  RM, Moreno RP, Bauer P, et al. Mortality after surgery in Europe: a 
7 day cohort study. Lancet 2012; 380: 1059–65.
2 Khuri S F, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ. 
Determinants of long-term survival after major surgery and the adverse 
eﬀ ect of postoperative complications. Ann Surg 2005; 242: 326–41.
3 Futier  E, Constantin JM, Paugam-Burtz C, et al, for the IMPROVE Study 
Group. A trial of intraoperative low-tidal-volume ventilation in 
abdominal surgery. N Engl J Med 2013; 369: 428–37.
4 The PROVE Network Investigators for the Clinical Trial Network of the 
European Society of Anaesthesiology. High versus low positive 
end-expiratory pressure during general anaesthesia for open abdominal 
surgery (PROVHILO trial): a multicentre randomised controlled trial. 
Lancet 2014; published online June 1. http://dx.doi.org/S0140-
6736(14)60416-5.
5 Severgn ini P, Selmo G, Lanza C, et al. Protective mechanical ventilation 
during general anesthesia for open abdominal surgery improves 
postoperative pulmonary function. Anesthesiology 2013; 118: 1307–21.
6 Esteban A, Frutos-Vivar F, Muriel A, et al. Evolution of mortality over 
time in patients receiving mechanical ventilation. 
Am J Respir Crit Care Med 2013; 188: 220–30.
7 Pinsky MR. The hemodynamic consequences of mechanical ventilation: 
an evolving story. Intensive Care Med 1997; 23: 493–503.
8 Tusman G, Bohm SH, Vazquez de Anda GF, do Campo JL, Lachmann B. 
“Alveolar recruitment strategy” improves arterial oxygenation during 
general anaesthesia. Br J Anaesth 1999; 82: 8–13.
9 Futier E, Constantin JM, Petit A, et al. Positive end-expiratory pressure 
improves end-expiratory lung volume but not oxygenation after 
induction of anaesthesia. Eur J Anaesthesiol 2010; 27: 508–13.
10 Rubenf eld GD. How much PEEP in acute lung injury. JAMA 2010; 
303: 883–84.
11 Lim SC, Adams AB, Simonson DA, et al. Transient hemodynamic eﬀ ects 
of recruitment maneuvers in three experimental models of acute lung 
injury. Crit Care Med 2004; 32: 2378–84.
12 Fanell i V, Mascia L, Puntorieri V, et al. Pulmonary atelectasis during low 
stretch ventilation: “open lung” versus “lung rest” strategy. 
Crit Care Med 2009; 37: 1046–53.
13 Lumb A B, Greenhill SJ, Simpson MP, Stewart J. Lung recruitment and 
positive airway pressure before extubation does not improve 
oxygenation in the post-anaesthesia care unit: a randomized clinical trial. 
Br J Anaesth 2010; 104: 643–47.
14 Bendix en HH, Hedley-Whyte J, Laver MB. Impaired oxygenation in 
surgical patients during general anesthesia with controlled ventilation. a 
concept of atelectasis. N Engl J Med 1963; 269: 991–96.
15 Levin MA, McCormick PJ, Lin HM, Hosseinian L, Fischer GW. Low 
intraoperative tidal volume ventilation with minimal PEEP is associated 
with increased mortality. Br J Anaesth 2014; published online March 12. 
http://dx.doi.org/10.1093/bja/aeu054.
Published Online
May 1, 2014
http://dx.doi.org/10.1016/
S0140-6736(14)60573-0
This online publication has 
been corrected. The corrected 
version ﬁ rst appeared at 
thelancet.com on May 29, 
2014
See Articles page 504
Frataxin protein
Sc
ie
nc
e 
Ph
ot
o 
Li
br
ar
y 
Comment
www.thelancet.com   Vol 384   August 9, 2014 475
mechanisms of action, these data match the eﬀ ects of 
nicotinamide and other HDAC inhibitors seen in model 
systems, both in the increase in frataxin concentration 
over the course of several hours, and in the estimated 
induction of frataxin expression by 1·5 to 2·0 times 
(corresponding to nicotinamide doses of 3·8–7·5 g).2,3 
Libri and colleagues’ ﬁ ndings substantiate the existence 
of epigenetic mechanisms in patients with Friedreich’s 
ataxia like those seen in model systems, as well as 
raising the possibility of therapeutic interventions 
based on the manipulation of such mechanisms. The 
increase in FXN mRNA expression was fairly small, 
but within a range that could aﬀ ect clinical outcome 
in Friedreich’s ataxia on the basis of an association 
between frataxin concentrations and disease severity.6 
Thus, the estimated increase in frataxin mRNA and 
protein reported with nicotinamide could be clinically 
meaningful if the drug is provided at the right time, for 
a suﬃ  cient duration, and to the appropriate tissues.
Nevertheless, the evidence for nicotinamide in 
Friedreich’s ataxia is incomplete. Although even 
a small increase in frataxin concentration might 
be clinically meaningful, how long the eﬀ ect of 
nicotinamide on frataxin expression could be 
maintained is unclear. The biological eﬀ ect lasted 
for 2 months in Libri and colleagues’ study—a short 
time in the life of a patient with Friedreich’s ataxia. 
Additionally, the eﬀ ects on frataxin noted by the 
investigators were assessed in peripheral blood 
mononuclear cells, which are not functionally aﬀ ected 
in Friedreich’s ataxia. Although nicotinamide crosses 
the blood–brain barrier, Libri and colleagues’ study 
does not address whether nicotinamide increases 
the amount of frataxin in the nervous system and 
other aﬀ ected tissues; it would have been useful to 
have measured drug concentrations and biological 
eﬀ ects in disease-relevant tissues such as the dorsal 
root ganglia and heart. Finally, restoration of frataxin 
concentrations must occur while the nervous system is 
still responsive to increases in frataxin. No eﬀ ects on 
ataxia were noted in the study; whether this ﬁ nding 
was caused by an inability of patients to respond or 
by the short duration of the study is not yet known. 
Longer studies will be needed to answer this question.
Although nicotinamide was used at doses that 
are much higher than the recommended daily 
allowance for vitamin B3, it was still reasonably well 
tolerated, with minor to moderate side-eﬀ ects such 
as nausea (100% during phases 2 and 3 combined) 
and vomiting (50%). These adverse eﬀ ects could be 
limiting for long-term treatment. Thus, in view of the 
fairly small changes in FXN expression and frataxin 
concentration, the absence of a demonstrated clinical 
eﬀ ect, and the unknown risks of long-term use, we need 
to look for a clinically meaningful beneﬁ t in randomised 
controlled studies of longer duration to determine 
whether nicotinamide is eﬀ ective for Friedreich’s ataxia.
Unlike other targeted drugs currently under 
development for Friedreich’s ataxia,7,8 nicotinamide 
is widely available, and patients and carers might be 
tempted to start using it for treatment. Although 
the data from Libri and colleagues’ study4 show 
the potential for epigenetic-based treatments in 
Friedreich’s ataxia, such approaches are not yet ready 
for widespread application in this disorder.
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